Abstracts tagged "cancer and Janus kinase (JAK)"

Abstract Number: 2659 • 2019 ACR/ARP Annual Meeting
Giant-Cell Arteritis Associated with Myeloproliferative Neoplasms: A Retrospective Case–Control Study
Matthias Papo¹, Laure Delaval ¹, Hubert de BOYSSON ², Jean-François Viallard ³, Aurélie Foucher ⁴, Sébastien Humbert ⁵, Pierre Duffau ⁶, Anne Contis ⁷, Christian Agard ⁸, Claude Bachmeyer ⁹, Bruno Gombert ¹⁰, Loic Guillevin ¹¹, Maxime Samson ¹² and Benjamin Terrier ¹¹, ¹Department of Internal Medicine, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, Paris, France, Paris, France, ²University Hospital of Caen, Caen, France, ³CHU Bordeaux, Bordeaux, France, ⁴Department of Internal Medicine and Infectious Diseases, Centre Hospitalier Universitaire de la Réunion Saint Pierre, Reunion Island, France., Saint-Pierre, France, ⁵Department of internal medicine, CHU Jean Minjoz, Besancon, France, Besancon, France, ⁶Department of Internal Medicine and Clinical Immunology , Hôpital Saint-André, CHU de Bordeaux , Bordeaux , France., Bordeaux, Aquitaine, France, ⁷Department of Internal Medicine and Clinical Immunology , Hôpital Saint-André, CHU de Bordeaux , Bordeaux , France, Bordeaux, France, ⁸CHU Nantes, Nantes, France, ⁹Department of Internal Medicine, Tenon Hospital (AP-HP), Paris, France, Paris, France, ¹⁰Rheumatology Department, Groupe Hospitalier de la Rochelle Ré Aunis, La Rochelle, France., La Rochelle, France, ¹¹National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, ¹²CHU Dijon, Dijon, France
Background/Purpose: Giant-cell arteritis (GCA) is a large-vessel vasculitis affecting patients >50 years, whose origin remains widely unelucidated. Recent studies demonstrated that myeloid disease-related somatic mutations…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].